131 related articles for article (PubMed ID: 29128180)
1. Notch3 as a novel therapeutic target in metastatic medullary thyroid cancer.
Lou I; Odorico S; Yu XM; Harrison A; Jaskula-Sztul R; Chen H
Surgery; 2018 Jan; 163(1):104-111. PubMed ID: 29128180
[TBL] [Abstract][Full Text] [Related]
2. Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction.
Jaskula-Sztul R; Eide J; Tesfazghi S; Dammalapati A; Harrison AD; Yu XM; Scheinebeck C; Winston-McPherson G; Kupcho KR; Robers MB; Hundal AK; Tang W; Chen H
Mol Cancer Ther; 2015 Feb; 14(2):499-512. PubMed ID: 25512616
[TBL] [Abstract][Full Text] [Related]
3. Notch3 expression correlates with thyroid cancer differentiation, induces apoptosis, and predicts disease prognosis.
Somnay YR; Yu XM; Lloyd RV; Leverson G; Aburjania Z; Jang S; Jaskula-Sztul R; Chen H
Cancer; 2017 Mar; 123(5):769-782. PubMed ID: 27861750
[TBL] [Abstract][Full Text] [Related]
4. In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer.
Vaccaro A; Chen H; Kunnimalaiyaan M
Anticancer Drugs; 2006 Aug; 17(7):849-53. PubMed ID: 16926634
[TBL] [Abstract][Full Text] [Related]
5. Expression of the active Notch1 decreases MTC tumor growth in vivo.
Jaskula-Sztul R; Pisarnturakit P; Landowski M; Chen H; Kunnimalaiyaan M
J Surg Res; 2011 Nov; 171(1):23-7. PubMed ID: 21571316
[TBL] [Abstract][Full Text] [Related]
6. RET mutation and increased angiogenesis in medullary thyroid carcinomas.
Verrienti A; Tallini G; Colato C; Boichard A; Checquolo S; Pecce V; Sponziello M; Rosignolo F; de Biase D; Rhoden K; Casadei GP; Russo D; Visani M; Acquaviva G; Ferdeghini M; Filetti S; Durante C
Endocr Relat Cancer; 2016 Aug; 23(8):665-76. PubMed ID: 27402614
[TBL] [Abstract][Full Text] [Related]
7. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft.
Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F
J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352
[TBL] [Abstract][Full Text] [Related]
8. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
9. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells.
Molè D; Gentilin E; Ibañez-Costa A; Gagliano T; Gahete MD; Tagliati F; Rossi R; Pelizzo MR; Pansini G; Luque RM; Castaño JP; degli Uberti E; Zatelli MC
Endocrine; 2015 Nov; 50(2):442-52. PubMed ID: 25854304
[TBL] [Abstract][Full Text] [Related]
10. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
Starenki D; Hong SK; Lloyd RV; Park JI
Oncogene; 2015 Aug; 34(35):4624-34. PubMed ID: 25435367
[TBL] [Abstract][Full Text] [Related]
11. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Lin CI; Whang EE; Lorch JH; Ruan DT
Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice.
Quidville V; Segond N; Tebbi A; Cohen R; Jullienne A; Lepoivre M; Lausson S
Thyroid; 2009 Jun; 19(6):613-21. PubMed ID: 19281427
[TBL] [Abstract][Full Text] [Related]
13. Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.
Zhang H; Liu L; Liu C; Pan J; Lu G; Zhou Z; Chen Z; Qian C
Oncotarget; 2017 May; 8(21):34362-34373. PubMed ID: 28416766
[TBL] [Abstract][Full Text] [Related]
14. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis.
Herac M; Niederle B; Raderer M; Krebs M; Kaserer K; Koperek O
APMIS; 2016 Oct; 124(10):839-45. PubMed ID: 27539746
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.
Petrangolini G; Cuccuru G; Lanzi C; Tortoreto M; Belluco S; Pratesi G; Cassinelli G; Zunino F
Biochem Pharmacol; 2006 Aug; 72(4):405-14. PubMed ID: 16756963
[TBL] [Abstract][Full Text] [Related]
16. Localization of CaSR antagonists in CaSR-expressing medullary thyroid cancer.
Ding H; Yusof AM; Kothandaraman S; Saji M; Wang C; Kumar K; Milum K; Carleton M; Pan X; Ringel MD; Tweedle MF; Phay JE
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1722-9. PubMed ID: 24030941
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma.
Ferreira LB; Eloy C; Pestana A; Lyra J; Moura M; Prazeres H; Tavares C; Sobrinho-Simões M; Gimba E; Soares P
Eur J Endocrinol; 2016 Apr; 174(4):551-61. PubMed ID: 26811408
[TBL] [Abstract][Full Text] [Related]
18. Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers.
Choy L; Hagenbeek TJ; Solon M; French D; Finkle D; Shelton A; Venook R; Brauer MJ; Siebel CW
Cancer Res; 2017 Mar; 77(6):1439-1452. PubMed ID: 28108512
[TBL] [Abstract][Full Text] [Related]
19. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
20. Ursolic acid from Trailliaedoxa gracilis induces apoptosis in medullary thyroid carcinoma cells.
Aguiriano-Moser V; Svejda B; Li ZX; Sturm S; Stuppner H; Ingolic E; Höger H; Siegl V; Meier-Allard N; Sadjak A; Pfragner R
Mol Med Rep; 2015 Oct; 12(4):5003-11. PubMed ID: 26151624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
